adavosertib

cyclin dependent kinase 1 ; Homo sapiens







23 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34352995 Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer. 2022 Apr 1
2 33869031 WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. 2021 1
3 32204315 Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. 2020 Mar 19 1
4 32220892 Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy. 2020 Jul 15 1
5 32311864 Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. 2020 Jul 1
6 31398082 Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. 2019 Oct 10 1
7 31712441 WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells. 2019 Nov 26 1
8 29175378 Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. 2018 Jan 3
9 29605721 Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. 2018 May 1
10 29783721 AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations. 2018 May 19 1
11 29954437 Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. 2018 Jun 28 1
12 28927115 WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. 2017 Sep 1
13 29088738 Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel. 2017 Sep 26 1
14 24791855 Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. 2015 Jan 1
15 25283841 A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. 2015 Apr 4
16 26585231 Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. 2015 Oct 1
17 26645158 Targeting of Carbon Ion-Induced G2 Checkpoint Activation in Lung Cancer Cells Using Wee-1 Inhibitor MK-1775. 2015 Dec 1
18 24962331 Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. 2014 Oct 2
19 25084614 CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. 2014 Aug 1 1
20 25301733 Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis. 2014 Nov 15 1
21 22797065 Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. 2013 Jun 13 1
22 21389100 MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. 2011 May 1 1
23 20107315 MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. 2010 Apr 1 1